Haifeng M. Wu MD

Haifeng M. Wu MD
Assoc ProfessorCollege of Medicinewu.395@osu.edu
185A Hamilton Hall 1645 Neil Avenue Columbus Ohio 43210
Phone:614-293-9873Fax: 614-292-3144
  • Translational Therapeutics

General Research Interest

Dr. Wu’s research applies the technological platform of SELDI-TOF to develop assays for enhancement of personalized cancer care. Specifically, utilizing one technological platform to set up clinical assays in the areas of: 1) genotyping the single nucleotide polymorphisms (SNPs) for guiding cancer care and for prediction of clinical outcomes (theranostics). The known SNPs that influence drug efficacy and drug toxicity such as CYP2D6, DPD/IVS14+1G>A, UGT1A1 will be the primary candidates in this undertaking; 2) rapid and cost-effective monitoring of plasma drug levels such as 5-FU to improve clinical efficacy and drug safety in cancer care and chemoprevention.

Current Publications

  • Cataland SR, Holers VM, Geyer S, Yang S, Wu HMBiomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.Blood 123 3733-8 6/12/2014
  • Cataland SR, Wu HMHow I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome.Blood 123 2478-84 4/17/2014
  • Cataland SR, Wu HMDiagnosis and management of complement mediated thrombotic microangiopathies.Blood Rev 28 67-74 3/1/2014
  • Wu TC, Yang S, Haven S, Holers VM, Lundberg AS, Wu H, Cataland SRComplement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura.J Thromb Haemost 11 1925-7 10/1/2013
  • Cataland SR, Wu HMAtypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies.Eur J Intern Med 24 486-91 9/1/2013
  • Lotta LA, Wu HM, Musallam KM, Peyvandi FThe emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura.Blood Rev 27 71-6 3/1/2013
  • Lotta LA, Wu HM, Cairo A, Bentivoglio G, Peyvandi FDrop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura.Blood Cells Mol Dis 50 59-60 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu